Anti-IgE mAb Suppresses Systemic Anaphylaxis through the Inhibitory IgG Receptor Fc ${\gamma}$ RIIb in Mice - Interaction between Anti-IgE and Fc ${\gamma}$ RIIb -

  • Kang, Nam-In (Department of Immunology, Chonbuk National University Medical School) ;
  • Jin, Zhe-Wu (Department of Surgery, Chonbuk Natioal University Medical School) ;
  • Lee, Hern-Ku (Department of Immunology, Chonbuk National University Medical School)
  • Published : 2007.09.30

Abstract

Background: Anti-IgE mAb which binds circulating but not receptor-bound IgE has been shown to be effective in treatment for asthma and other allergic diseases. However, the mechanisms by which anti-IgE mAb influences the pathophysiological responses are remained to be illustrated. This study was undertaken to examine the therapeutic efficacy of non-anaphylactogenic anti-mouse IgE mAb using murine models of IgE-induced systemic fatal anaphylaxis. Methods: Active systemic anaphylaxis was induced by either penicillin V(Pen V) or OVA and passive systemic anaphylaxis was induced by either anaphylactogenic anti-mouse IgE or a mixture of anti-chicken gamma globulin (CGG) IgG1 mAb and CGG. The binding of the Fc portion of anti-IgE to CHO-stable cell line expressing mouse Fc ${\gamma}$ RIIb was examined using flow cytometry. Fc fragments of anti-IgE mAb were prepared using papain digestion. The expression of phosphatases in lungs were assessed by Western blotting and immunohistochemistry. Results: Anti-IgE mAb prevented IgE- and IgG-induced active and passive systemic fatal reactions. In both types of anaphylaxis, anti-IgE mAb suppressed antigen-specific IgE responses, but not those of IgG. Anti-IgE mAb neither prevented anaphylaxis nor suppressed the IgE response in Fc ${\gamma}$ RIIb-deficient mice. The Fc portion of anti-IgE mAb was bound to murine Fc ${\gamma}$ RIIb gene-transfected CHO cells and inhibited systemic anaphylaxis. Anti-IgE mAb blocked the anaphylaxis-induced downregulation of Fc ${\gamma}$ RIIb-associated phosphatases such as src homology 2 domain-containing inositol 5-phosphatase (SHIP) and phosphatase and tensin homologue deleted on chromosome ten (PTEN). Conclusion: Anti-IgE mAb prevented anaphylaxis by delivering nonspecific inhibitory signals through the inhibitory IgG receptor, Fc ${\gamma}$ RIIb, rather than targeting IgE.

Keywords

References

  1. Ishizaka K, Ishizaka T: Biological function of IgE antibodies and mechanisms of reaginic hypersensitivity. Clin Exp Immunol 6;25-42, 1970
  2. Okudaira H, Sakurai Y, Terada K, Terada E, Ogita T, Miyamoto T: Cyclosporin A-induced suppression of ongoing IgE antibody formation in the mouse. Int Arch Allergy Appl Immunol 79;164-168, 1986 https://doi.org/10.1159/000233965
  3. Takatsu K, hizaka K: Reaginic antibody formation in the mouse. VI. Suppression of IgE and IgG antibody responses to ovalbumin following the administration of high dose urea-denatured antigen. Cell Immunol 20;276-289, 1975 https://doi.org/10.1016/0008-8749(75)90105-7
  4. Lee WY, Sehon AH: Abrogation of reaginic antibodies with modified allergens. Nature 267;618-619, 1977 https://doi.org/10.1038/267618a0
  5. Hayglass KT, Stefura WP: Antigen-specific inhibition of ongoing murine 19E responses. II. Inhibition of 19E responses induced by treatment with glutaraldehyde-modified allergens is paralleled by reciprocal increases in IgG2a synthesis. J Immunol 147;2455-2460, 1991
  6. Finkelman FD, Katona IM, Mosmann TR, Coffman RL: IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses. J Immunol 140;1022-1027, 1988
  7. Souillet G, Rousset F, Vries JE: Alpha-interferon treatment of patient with hyper IgE syndrome. Lancet 1;1384, 1989
  8. Finkelman FD, Holmes J, Katona IM, Urban JF, Beckmann JrMP, Park LS, Schooley KA, Coffman RL, Mosmann TR, Paul WE: Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 8;303-333, 1990 https://doi.org/10.1146/annurev.iy.08.040190.001511
  9. Park JS, Choi IH, Lee DG, Han SS, Ha TY, Lee HH, Park YM, Lee HK: Anti-IL-4 monoclonal antibody prevents antibiotics-induced active fatal anaphylaxis. J Immunol 158;5002-6,1997
  10. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM: Humanization of an antibody directed against IgE. J Immunol 151;2623-2632, 1993
  11. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey HA: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155;1828-1834, 1997 https://doi.org/10.1164/ajrccm.155.6.9196082
  12. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ, Fick RB Jr, Adelman DC: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100;110-121, 1997 https://doi.org/10.1016/S0091-6749(97)70202-1
  13. Saban R, Haak-Frendscho M, Zine M, Ridgway J, Gorman C, Presta LG, Bjorling D, Saban M, Jardieu P: Human FcERI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. J Allergy Clin Immunol 94;836-843, 1994 https://doi.org/10.1016/0091-6749(94)90151-1
  14. Haak-Frendscho M, Robbins K, Lyon R, Shields R, Hooley J, Schoenhoff M, Jardieu P: Administration of an anti-Igf antibody inhibits CD23 expression and IgE production in vivo. Immunology 82;306-313, 1994
  15. Haak-Frendscho M, Saban R, Shields RL, Jardieu PM: Anti-immunoglobulin E antibody treatment blocks histamine release and tissue contraction in sensitized mice. Immunology 94;115-121, 1998 https://doi.org/10.1046/j.1365-2567.1998.00478.x
  16. Owen CE: Anti-immunoglobulin E therapy for asthma. Pulm Pharmacol Ther 15 ;417-424, 2002 https://doi.org/10.1006/pupt.2002.0372
  17. D'Amato G: Therapy of allergic bronchial asthma with omalizumab - an anti-IgE monoclonal antibody. Expert Opin Biol Ther 3;371-376, 2003 https://doi.org/10.1517/14712598.3.2.371
  18. Leung DY, Sampson HA, Yunginger JW, Burks AW, Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR Jr; Avon Longitudinal Study of Parents and Children Study Team: Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348;986-993, 2003 https://doi.org/10.1056/NEJMoa022613
  19. Weiss ME, Nyhan D, Peng ZK, Horrow JC, Lowenstein E, Hirshman C, Adkinson NF Jr: Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 320;886-892, 1989 https://doi.org/10.1056/NEJM198904063201402
  20. Lee HK, Lee HH, Park YM, Park HJ, Lee JH, Ha TY: Anti-IL-4 antibody inhibits antigen specific IgE response bur fails to prevent chicken gamma globulin-induced active systemic anaphylaxis: evidence for the involvement of IgG antibodies. J Korean Med Sci 11;111-117, 1996 https://doi.org/10.3346/jkms.1996.11.2.111
  21. Atimura A, Nagata M, Watanabe A, Nakamura K, Takeuchi M, Harada M: Production of active and passive anaphylactic shock in the WBB6Fl mouse, a mast cell-deficient strain. Experientia 46;739-742, 1990 https://doi.org/10.1007/BF01939952
  22. Oettgen HC, Martin TR, Wynshaw-Boris A, Deng C, Drazen JM, Leder P: Active anaphylaxis in IgE-deficient mice. Nature 370;367-370, 1994 https://doi.org/10.1038/370367a0
  23. Choi IH, Shin YM, Park JS, Lee MS, Han EH, Chai OH, Im SY, Ha TY, Lee HK: IgE-dependent active fatal anaphylaxis in mast cell-deficient mice. J Exp Med 188; 1587-1592, 1998 https://doi.org/10.1084/jem.188.9.1587
  24. Harlow ED, Lane D: Antibodies a Laboratory Manual. Cold Spring Harbor Laboratory. New York: 1988. p. 628-9
  25. Ravetch JV, Bolland S: IgG Fc receptors. Annu Rev Immunol 19;275, 2001
  26. Mechetina LV, Najakshin AM, Alabyev BY, Chikaev NA, Taranin AV: Identification of CD16-2, a novel mouse receptor homologous to CD16/Fc gamma RIII. Immunogenetics 54;463-468, 2002 https://doi.org/10.1007/s00251-002-0486-0
  27. Amigorena S, Bonnerot C, Choquet D, Fridman WH, Teillaud JL: Fc gamma RII expression in resting and activated B lymphocytes. Eur J Immunol 19;1379-1385, 1989 https://doi.org/10.1002/eji.1830190805
  28. Amigorena S, Bonnerot C, Drake J, Choquet D, Hunziker W, Guillet JGR, Webster P, Sautes C, Mellman I, Fridman WH: Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B-Iymphocytes. Science 256;1808-1812, 1992 https://doi.org/10.1126/science.1535455
  29. Phillips NE, Parker DC: Cross-linking of B lymphocyte Fe gamma receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis. J Immunol 132;627-632, 1984
  30. Sinclair NRSC, Chan PL: Regulation of the Immune responses. IV. The role of the Fc-fragment in feedback inhibition by antibody. Adv Exp Med Biol 12;609-615, 1971
  31. Daeron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, Fridman WH: The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 3;635-646, 1995 https://doi.org/10.1016/1074-7613(95)90134-5
  32. Daeron M, Malbec O, Latour S, Arock M, Fridman WH: Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 95;577-585, 1995 https://doi.org/10.1172/JCI117701
  33. Ujike A, Ishikawa Y, Ono M, Yuasa T, Yoshino T, Fukumoto M, Ravetch JV, Takai T: Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. J Exp Med 189;1573-1579, 1999 https://doi.org/10.1084/jem.189.10.1573
  34. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetch JV: A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 369;340, 1994
  35. Bolland S, Pearse RN, Kurosaki T, Ravetch JV: SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity 8;509-516, 1998 https://doi.org/10.1016/S1074-7613(00)80555-5
  36. Scharenberg AM, EI-Hillal O, Fruman DA, Beitz LO, Li Z, Lin S, Gout I, Cantley LC, Rawlings DJ, Kinet JP: Phosphatidylinositol-3, 4, 5-trisphosphate (PtdIns-3, 4, 5P3)/Tec kinase-dependent calcium signaling pathway: A target for SHIP-mediated inhibitory signals. EMBO J 17; 1961-1972, 1998 https://doi.org/10.1093/emboj/17.7.1961
  37. Van Den Herik-Oudijk IE, Westerdaal NA, Henriquez NV, Capel PJ, Van De Winkel JG: Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes. J Immunol 152;574-585, 1994
  38. Phillips NE, Parker DC: Cross-linking of B lymphocyte Fc gamma receptors and membrane immunoglobulin inhibits antiimmunoglobulin- induced blastogenesis. J Immunol 132;627-632, 1984
  39. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey HA: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155;1828-1834, 1997 https://doi.org/10.1164/ajrccm.155.6.9196082
  40. Boulet LP, Chapman KR, Cote J, Kalra S, Bhaqat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, DeVault A, Fick RB Jr, Cockcroft DW: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155;1835-1840, 1997 https://doi.org/10.1164/ajrccm.155.6.9196083
  41. Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ: Treatment of allergic asthma with monoclonal anti-lgE antibody. N Engl J Med 341; 1966-1973, 1999 https://doi.org/10.1056/NEJM199912233412603
  42. Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, Fowler-Taylor A, Liu J, Gupta N: Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 111;278-284, 2003 https://doi.org/10.1067/mai.2003.54
  43. Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F, Champain K, Fox H, Thirlwell J: The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 20;1088-1094, 2002 https://doi.org/10.1183/09031936.02.00016502
  44. Lemanske RF, Nayakm A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N: Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 110;E55, 2002
  45. Liu J, Lester P, Builder S, Shire SJ: Characterisation of complex formation by humanised anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34;10474-10482, 1995 https://doi.org/10.1021/bi00033a020
  46. Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, Gygax D, Heusser C, Patalano F, Richardson W, Kilchherr E, Staehelin T, Davis F, Gordon W, Sun L, Liou R, Wang G, Chang TW, Holgate S: The effect of intravenous administration of a chimaeric anti-IgE antibody on serum IgE levels in atopic subjects - efficacy, safety and pharmacokinetics. J Clin Invest 99;879-887, 1997 https://doi.org/10.1172/JCI119252
  47. Haak-Frendscho M, Robbins K, Lyon R, Shields R, Hooley J, Schoenhoff M, Jardieu P: Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. Immunology 82;306-313, 1994
  48. MacGlashan DJr, Xia HZ, Schwartz LB, Gong J: IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcepsilonRI in human basophils. J Leukoc Biol 70;207-218, 2001
  49. Saini SS, Klion AD, Holland SM, Hamilton RG, Bochner BS, Macglashan DW Jr: The relationship between serum IgE and surface levels of FcepsilonR on human leukocytes in various diseases: correlation of expression with FcepsilonRI on basophils but not on monocytes or eosinophils. J Allergy Clin Immunol 106;514-520, 2000 https://doi.org/10.1067/mai.2000.108431
  50. MacGlashan DJr, McKenzie-White J, Chichester K, Bochner BS, Davis FM, Schroeder JT, Lichtenstein LM: In vitro regulation of FcepsilonRIaipha expression on human basophils by IgE antibody. Blood 91;1633-1643, 1998
  51. MacGlashan DWJr, Bochner BS, Adelman DC, Jardieu PM, Toqias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM: Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158; 1438-1445, 1997
  52. Chang TW, Shiung YY: Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol 117;1203-1212, 2006 https://doi.org/10.1016/j.jaci.2006.04.005
  53. Lanier BQ: Unanswered questions and warnings involving anti-immunoglobulin E therapy based on 2-year observation of clinical experience. Allergy Asthma Proc 26;435-439, 2005